Anatomical and biochemical investigation of primary brain tumours

Abstract

Cancerous transformation entails major biochemical changes including modifications of the energy metabolism of the cell, e.g. utilisation of glucose and other substrates, protein synthesis, and expression of receptors and antigens. Tumour growth also leads to heterogeneity in blood flow owing to focal necrosis, angiogenesis and metabolic demands, as well as disruption of transport mechanisms of substrates across cell membranes and other physiological boundaries such as the blood-brain barrier. All these biochemical, histological and anatomical changes can be assessed with emission tomography, X-ray computed tomography (CT), magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS). Whereas anatomical imaging is aimed at the diagnosis of brain tumours, biochemical imaging is better suited for tissue characterisation. The identification of a tumoural mass and the assessment of its size and vascularisation are best achieved with X-ray CT and MRI, while biochemical imaging can provide additional information that is crucial for tumour classification, differential diagnosis and follow-up. As the assessment of variables such as water content, appearance of cystic lesions and location of the tumour are largely irrelevant for tissue characterisation, a number of probes have been employed for the assessment of the biochemical features of tumours. Since biochemical changes may be related to the growth rate of cancer cells, they can be thought of as markers of tumour cell proliferation. Biochemical imaging with radionuclides of processes that occur at a cellular level provides information that complements findings obtained by anatomical imaging aimed at depicting structural, vascular and histological changes. This review focusses on the clinical application of anatomical brain imaging and biochemical assessment with positron emission tomography, single-photon emission tomography and MRS in the diagnosis of primary brain tumours, as well as in follow-up.

Flow Cytometry Analysis of Neural Differentiation Markers Expression in Human Glioblastomas May Predict Their Response to Chemotherapy

“…The average life expectancy in GBM patients is approximately 17 weeks without therapy, and 62 weeks with radiation and chemotherapy (DeAngelis 2001;Del Sole et al 2001). Despite the very unfavourable prognosis, a small number of patients exist who display prolonged survival times.…”

Brain imaging: assessing therapy responses using quantitative imaging biomarkers

“…While MR provides excellent anatomic detail, an enhancing lesion post treatment cannot be reliably categorized as radiation necrosis versus recurrent tumor Del Sole et al , 2001 ). This is a critical issue in monitoring tumor response to chemoradiation and stereotactic radiosurgery, both of which represent extensively-used treatment methods at present and are associated with high prevalence of post therapy necrosis.…”

In Vivo Methods to Estimate Drug Transport to the Brain Across the Blood-Brain Barrier

“…It allows the evaluation of a variety of parameters in the brain related to anatomy, physiology and metabolism like macrophage infiltration, cytotoxic edema, cerebral blood flow and volume, and metabolic processes [24]. In addition, dynamic MRI has been performed to investigate BBB permeability and leakage involved in brain diseases including neurodegenerative diseases [24], various brain tumors [25], multiple sclerosis [26], early infarcts and inflammatory lesions can be studied [27]. With these techniques one can differentiate between parent compound and its metabolites as well as between free and unbound drug concentrations.…”